Ghent, Belgium, 20th January 2012 – Pronota NV today announced the close of a Series C financing, raising EUR 3.7 million from existing investors; LSP, Gimv, Biotech Fund Flanders, KBC Private Equity, Johnson & Johnson Development Corporation, VIB, MP Healthcare and MedSciences Capital, and a company founder.
The proceeds will be used to complete the protein biomarker validation studies for Pronota’s innovative diagnostic products in its preeclampsia, ovarian cancer, sepsis and cardio-renal programs.
In addition, Pronota announced that Nick McCooke is stepping down as CEO and board member to pursue opportunities closer to his home base in the UK after nearly 6 years as CEO. He is being replaced by Katleen Verleysen, previously COO. At the same time, John Berriman is stepping down as chairman to be replaced by Rudy Dekeyser, managing director of VIB.
Incoming CEO Katleen Verleysen commented: “I welcome and draw great confidence from our investors’ continued support as we push our products forward to complete clinical proof of concept, building on the exciting results of the first stages of clinical validation. I’d also like to take the opportunity to express the Board’s thanks to both Nick and John making Pronota the leader in taking novel protein biomarkers from discovery through to clinical application. I’m excited to be working on the next stage of the journey as we further build the value of our products, which are already attracting strong interest from diagnostic companies.”
